SCHEMBL6429249

SCHEMBL6429249

COc1ccc([C@@H](CS(=O)(=O)Cc2cnc3ccccc3c2)N(OC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)cc1.COc1ccc([C@H](O)CS(=O)(=O)Cc2cnc3ccccc3c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.37
CNR2 P34972 1/20 0.36
FAAH O00519 2/20 0.36
HIF1A Q16665 1/20 0.34
EPAS1 Q99814 1/20 0.34
ALPL P05186 5/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
MMP1 P03956 2/20 0.31
MMP9 P14780 2/20 0.31
FCER2 P06734 1/20 0.31
MMP3 P08254 1/20 0.31
PTGES O14684 1/20 0.31
ALOX5 P09917 1/20 0.31
KMT2A Q03164 2/20 0.30
PDE10A Q9Y233 2/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6431116 0.96 TRPM8 (0.39) TRPM8CNR2FAAHHIF1AEPAS1
SCHEMBL6605219 0.96 TRPM8 (0.39) TRPM8CNR2FAAHHIF1AEPAS1
SCHEMBL6605211 0.96 TRPM8 (0.39) TRPM8CNR2FAAHHIF1AEPAS1
SCHEMBL6403790 0.91 TRPM8 (0.36) TRPM8CNR2FAAHHIF1AEPAS1
SCHEMBL6402952 0.89 ACP1 (0.35) TRPM8CNR2HIF1AEPAS1MMP1
SCHEMBL6402948 0.89 ACP1 (0.35) TRPM8CNR2HIF1AEPAS1MMP1
SCHEMBL6429732 0.89 ACP1 (0.35) TRPM8CNR2HIF1AEPAS1MMP1
SCHEMBL6400585 0.84 TRPM8 (0.38) TRPM8CNR2FAAHHIF1AEPAS1
SCHEMBL6399629 0.83 ADORA2A (0.31)
SCHEMBL6604993 0.82 MEN1 (0.31) SMN1; SMN2TP53KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides SMITHKLINE BEECHAM PLC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288376-A1 Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides CD22, CD2, NEU3 TRPM8 1841/4885CNR2 482/4885FAAH 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.